Login to Your Account

Earnings Roundup

Regeneron Hits Profitability as Eylea Sales Blast Expectations

By Jennifer Boggs
Managing Editor

Friday, April 27, 2012

Regeneron Pharmaceuticals Inc.'s first-quarter earnings left consensus estimates in the dust, as higher-than-expected sales of age-related macular degeneration (AMD) drug Eylea (aflibercept ophthalmic solution) drove the company to profitability for the first time in its 24-year history.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription